Combined androgen blockade and treatment of localized prostate cancer: A real hope when approaching the year 2000

Endocrine-Related Cancer

Volumn 5, Issue 4, 1998, Pages 341-351

  Labrie, F ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; FLUTAMIDE; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; ARTICLE; DRUG EFFICACY; EARLY DIAGNOSIS; ENDOCRINOLOGY; HUMAN; ORCHIECTOMY; PROSTATE CANCER; QUALITY OF LIFE; RECEPTOR BLOCKING; TUMOR LOCALIZATION;

EID: 0032417907     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0050341     Document Type: Article

References (85)

1. Albersten PC, Aaronson NK, Muller MJ, Keller SD & Ware JE Jr 1997 Health-related quality of life among patients with metastatic prostate cancer. Urology 49 207-217.
2. Andersson S & Russel DW 1990 Structural and biochemical properties of cloned and expressed human and rat steroid 5α-reductases. Proceedings of the National Academy of Sciences of the USA 87 3640-3644.
3. Andersson S, Bergman DM, Jenkins EP & Russel DW 1991 Deletion of steroid 5α-reductase 2 gene in male pseudohermaphroditism. Nature 354 159-161.
4. Aus G, Hugosson J & Norlén L 1995 Long-term survival and mortality in prostate cancer treated with noncurative intent. Journal of Urology 154 460-465.
5. Béland G, Elhilali M, Fradet Y, Laroche B, Ramsey EW, Trachtenberg J, Venner PM & Tewari HD 1988 Total androgen blockade versus castration in metastatic cancer of the prostate. In: Hormonal Therapy of Prostatic Diseases: Basic and Clinical Aspects, pp 302-311. Eds M Motta & M Serio. Bussum: Medicom.
6. Bélanger A, Brochu M & Cliche J 1986 Levels of plasma steroid glucuronides in intact and castrated men with prostatic cancer. Journal of Clinical Endocrinology and Metabolism 62 812-815.
7. Bernier F, Leblanc G, Labrie F & Luu-The V 1994a Structure of human estrogen and aryl sulfotransferase gene. Two mRNA species issued from a single gene. Journal of Biological Chemistry 269 28200-28205.
8. Bernier F, Lopez-Solache I, Labrie F & Luu-The V 1994b Cloning and expression of cDNA encoding human placental estrogen sulfotransferase. Molecular and Cellular Endocrinology 99 R11-R15.
9. Blasko J, Ragde H, Luse R et al. 1996 Should brachytherapy be considered a therapeutic option in localized prostate cancer? Urologic Clinics of North America 23 633-649.
10. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L & Pierart M 1997 Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. New England Journal of Medicine 337 295-300.
11. Caubet JF, Tosteson TD, Dong EW, Naylon EM, Whiting GW, Ernstoff MS & Ross SD 1997 Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal anti-androgens. Urology 49 71-78.
12. Chodak GW, Thisted RA, Gerber GS, Johansson J-E, Adolfsson J, Jones GW, Chisholm GD, Moskovitz B, Livne PM & Warner J 1994 Results of conservative management of clinically localized prostate cancer. New England Journal of Medicine 330 242-248.
13. Consensus Conference 1987 The management of clinically localized prostate cancer. JAMA 258 2727-2730.
14. Cooner WH, Mosley BR, Rutherford Jr CL, Beard JH, Pond HS, Terry WJ, Igel TC & Kidd DD 1990 Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate-specific antigen. Urology 143 1146-1154.
15. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein DA, Davis MA & Goodman PJ 1989 A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New England Journal of Medicine 321 419-424.
16. Denis L, Carnelro de Moura JL, Bono A, Sylvester R, Whelan R, Newling D & De Pauw M 1993 Goserelin acetate and flutamide vs bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology 42 119-129.
17. Denis LJ, Keuppens F, Smith PH, Whelan P, Cameiro de Moura JL, Newling D, Bono A & Sylvester R 1998 Maximal androgen blockade: final analysis of EORTC Phase III trial 30853. European Urology 33 144-151.
18. Dijkman GA, Janknegt RA, Dereijke TM & Debruyne FMJ 1997 Long-term efficacy and safety of nilutamide plus castration in advanced prostate-cancer, and the significance of early prostate specific antigen normalization. Journal of Urology 158 160-163.
19. Emond J, Dupont A, Cusan L, Bergeron N, Manhès G & Labrie F 1989 Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) as an alternative to transurethral resection of the prostate for urinary retention in prostate cancer. In: Early Stage Prostate Cancer: Diagnosis and Choice of Therapy, pp 103-108. Eds F Labrie, F Lee & A Dupont. Amsterdam: Elsevier.
20. Faure N, Labrie F, Lemay A, Bélanger A, Gourdeau Y, Laroche B & Robert G 1982 Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (GNRH) agonist in adult men. Fertility and Sterility 37 416-424.
21. Furr BJ, Valcaccia B, Curry B, Woodburn JR, Chesterson G & Tucker H 1987 ICI176,334: a novel nonsteroidal peripherally selective antiandrogen. Journal of Endocrinology 113 R7-R9.
22. Gann PH, Hennekens CH & Stampfer MJ 1995 A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 273 289-294.
23. Goad JR, Chang SJ, Ohori M & Scardino PT 1993 PSA after definitive radiotherapy for clinically localized prostate cancer. Urologic Clinics of North America 20 727-736.
24. -2 (A-2,B) prostate cancer treated with external beam radiation therapy in RTOG 77-06. International Journal of Radiation Oncology Biology Physics 21 1099-1103.
25. Hoeksema MJ & Law C 1996 Cancer mortality rates fall: a turning point for the nation. Journal of the National Cancer Institute 88 1706-1707.
26. Huggins C & Hodges CV 1941 Studies of prostatic cancer. I. Effect of castration, estrogen and androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Research 1 293-307.
27. Hugosson J, Aus G, Bergdahl C & Bergdahl S 1995 Prostate cancer mortality in patients surviving more than 10 years after diagnosis. Journal of Urology 154 2115-2117.
28. Janknegt RA, Abbou CC, Bartoletti R, Bernstein-Hahn L, Bracken B, Brisset JM, Da Silva FC, Chisholm G, Crawford ED, Debruyne FM et al. 1993 Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. Journal of Urology 149 77-83.
29. Kaplan ID, Cox RS & Bagshaw MA 1993 Prostate specific antigen after external beam radiotherapy for prostatic cancer: followup. Journal of Urology 149 519-522.
30. Katchen B & Buxbaum S 1975 Disposition of a new, nonsteroid, antiandrogen, α,α,α-trifluoro-2-methyl-4′-nitro-m-propionotoluidide (flutamide), in men following a single oral 200 mg dose. Journal of Clinical Endocrinology and Metabolism 41 373-379.
31. Killian CS, Emrich LJ, Vargas FP, Yang N, Wang MC, Priore RL, Murphy GP & Chu TM 1986 Relative reliability of five serially measured markers for prognosis of progression in prostate cancer. Journal of the National Cancer Institute 76 179-185.
32. Kolata G 1987 Prostate cancer consensus hampered by lack of data. Science 236 1626-1627.
33. Kupelian P, Katcher J, Levin H, Zippe C & Klein E 1996 Correlation of clinical and pathological factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 48 249-260.
34. Labrie F 1991 Endocrine therapy for prostate cancer. Endocrinology and Metabolism Clinics of North America 20 845-872.
35. Labrie F 1993 Mechanism of action and pure antiandrogenic properties of flutamide. Cancer 72 3816-3827.
36. Labrie F 1994 Intracrinology and cancer therapy. Science Watch 5 3-8.
37. Labrie F 1995 Endocrine therapy of prostate cancer: optimal form and timing. Journal of Clinical Endocrinology and Metabolism 80 1066-1071.
38. Labrie F & Crawford D 1995 Anti-androgens in treatment of prostate cancer. Lancet 346 1030-1031.
39. Labrie F, Bélanger A, Cusan L, Séguin C, Pelletier G, Kelly PA, Reeves JJ, Lefebvre FA, Lemay A & Ranaud JP 1980 Anti-fertility effects of LHRH agonists in the male. Journal of Andrology 1 209-228.
40. Labrie F, Dupont A, Bélanger A, Cusan L, Lacourcière Y, Monfette G, Laberge JG, Emond J, Fazekas AT, Raynaud JP & Husson JM 1982 New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clinical and Investigative Medicine 5 267-275.
41. Labrie F, Dupont A & Bélanger A 1985 Complete androgen blockade for the treatment of prostate cancer. In: Important Advances in Oncology, pp193-217. Eds VT de Vita, S Hellman & SA Rosenberg. Philadelphia: JB Lippincott.
42. Labrie F, Dupont A, Suburu R, Cusan L, Tremblay M, Gomez JL & Emond J 1992a Serum prostatic specific antigen (PSA) as prescreening test for prostate cancer. Journal of Urology 147 846-851.
43. Labrie F, Simard J, Luu-The V, Bélanger A & Pelletier G 1992b Structure, function and tissue-specific gene expression of 3β-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase enzymes in classical and peripheral intracrine steroidogenic tissues. Journal of Steroid Biochemistry and Molecular Biology 43 805-826.
44. Labrie F, Sugimoto Y, Luu-The V, Simard J, Lachance Y, Bachvarov D, Leblanc G, Durocher F & Paquet N 1992c Structure of human type II 5α-reductase. Endocrinology 131 1571-1573.
45. Labrie F, Bélanger A, Dupont A, Luu-The V, Simard J & Labrie C 1993a Science behind total androgen blockade: from gene to combination therapy. Clinical and Investigative Medicine 16 475-492.
46. Labrie F, Dupont A, Cusan L, Gomez JL, Diamond P, Koutsilieris M, Suburu R, Fradet Y, Lemay M, Têtu B, Emond J & Candas B 1993b Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clinical and Investigative Medicine 16 499-509.
47. Labrie F, Dupont A, Simard J, Luu-The V & Bélanger A 1993c Intracrinology: the basis for the rational design of endocrine therapy at all stages of prostate cancer. European Urology 24 (Suppl 2) 94-105.
48. Labrie F, Dupont A, Suburu R, Cusan L, Gomez JL, Koutsilieris M, Diamond P, Emond J, Lemay M & Têtu B 1993d Optimized strategy for detection of early stage, curable prostate cancer: role of prescreening with prostatic-specific antigen. Clinical and Investigative Medicine 16 425-439.
49. Labrie F, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M, Tetu B, Fradet Y & Candas B 1994 Down-staging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist. Urology 44 29-37.
50. Labrie F, Bélanger A, Simard J, Luu-The V & Labrie C 1995a DHEA and peripheral androgen and estrogen formation: Intracrinology. Annals of the New York Academy of Sciences 774 16-28.
51. Labrie F, Cusan L, Gomez JL, Diamond P & Candas B 1995b Combination of screening and preoperative endocrine therapy: the potential for an important decrease in prostate cancer mortality. Journal of Clinical Endocrinology and Metabolism 80 2002-2013.
52. Labrie Y, Durocher F, Lachance Y, Turgeon C, Simard J, Labrie C & Labrie F 1995c The human type II 17β-hydroxysteroid dehydrogenase gene encodes two alternatively-spliced messenger RNA species. DNA Cell Biology 14 849-861.
53. Labrie F, Bélanger A, Cusan L, Simard J, Luu-The V, Labrie C, Gomez JL, Diamond P & Candas B 1996a History of LHRH agonist and combination therapy in prostate cancer. Endocrine-Related Cancer 3 243-278.
54. Labrie F, Candas B, Cusan L, Gomez JL, Diamond P, Suburu R & Lemay M 1996b Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology 47 212-217.
55. Labrie F, Cusan L, Dupont A, Gomez JL, Simard J, Luu-The V, Pelletier G, Labrie C & Bélanger A 1996c Androgen receptor antagonists. In: Reproductive Endocrinology, Surgery and Technology, pp 560-583. Eds EY Adashi, JA Rock & Z Rosenwaks. Philadelphia: Lippincott-Raven Publishers.
56. Labrie F, Simard J, Luu-The V, Bélanger A, Pelletier G, Morel Y, Mebarki F, Sanchez R, Durocher F, Turgeon C, Labrie Y, Rhéaume E, Labrie C & Lachance Y 1996d The 3β-hydroxysteroid dehydrogenase/isomerase gene family: lessons from type II 3β-HSD congenital deficiency. In: Signal Transduction in Testicular Cells. Ernst Schering Research Foundation Workshop, pp185-218. Eds VHansson, FO Levy & K Taskén. Berlin, Heidelberg, New York: Springer-Verlag.
57. Labrie F, Cusan L, Gomez JL, Diamond P & Bélanger A 1997a Long-term neoadjuvant and adjuvant combined androgen blockade is needed for efficacy of treatment in localized prostate cancer. Molecular Urology 1 253-263.
58. Labrie F, Luu-The V, Lin SX, Labrie C, Simard J, Breton R & Bélanger A 19970 The key role of 17β-HSDs in sex steroid biology. Steroids 62 148-158.
59. Laverdiere J, Gomez JL, Cusan L, Suburu R, Diamond P, Lemay M, Candas B, Fortin A & Labrie F 1997 Beneficial effect of combination therapy administered prior and following external beam radiation therapy in localized prostate cancer. International Journal of Radiation Oncology Biology Physic 37 247-252.
60. Lee F, Torp-Pedersen ST, Siders DB, Littrup PJ & McLeary RD 1989 Transrectal ultrasound in the diagnosis and staging of prostatic carcinoma. Radiology 170 609-615.
61. Lerner SP, Seale-Hawkins C, Carlton Jr CE & Scardino PT 1991 The risk of dying of prostate cancer in patients with clinically localized disease. Journal of Urology 146 1040-1045.
62. Littrup PJ, Kane RA, Mettlin CJ, Murphy GP, Lee F, Toi A, Badalament R & Babaian R 1994 Cost-effective prostate-cancer detection. Reduction of low-field biopsies. Cancer 74 3146-3158.
63. Luu-The V, Dufort I, Paquet N, Reimnitz G & Labrie F 1995a Structural characterization and expression of the human dehydroepiandrosterone sulfotransferase gene. DNA and Cell Biology 14 511-518.
64. Luu-The V, Zhang Y, Poirier D & Labrie F 1995b Characteristics of human types 1, 2 and 3 17β-hydroxysteroid dehydrogenase activities: oxidation-reduction and inhibition. Journal of Steroid Biochemistry and Molecular Biology 55 581-587.
65. Middleton RG, Thompson IM, Austenfeld MS, Cooner WH, Correa RJ, Gibbons RP, Miller HC, Oesterling JE, Resnick MI, Smalley SR et al. 1995 Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. The American Urological Association. Journal of Urology 154 2144-2148.
66. Moguilewsky M, Fiet J, Toumemine C & Raynaud JP 1986 Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer. Journal of Steroid Biochemistry and Molecular Biology 24 139-146.
67. Moorjani S, Dupont A, Labrie F, Lupien PJ, Gagné C, Brun C, Giguère M, Bélanger A & Cusan L 1988 Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with LHRH agonist and Flutamide. Journal of Clinical Endocrinology and Metabolism 66 314-322.
68. Morton RA, Steiner MS & Walsh PC 1991 Cancer control following anatomical radical prostatectomy: an interim report. Journal of Urology 145 1197-1200.
69. Moskovitz B, Nitecki S & Richter-Levin D 1987 Cancer of the prostate: is there a need for aggressive treatment? Urology International 42 49-52.
70. National Institute of Health 1987 Consensus statement: the Management of Clinically localized prostate cancer. National Canver Institute Monographs 6 1-6.
71. Neri R, Monahan MD, Meyer JG, Afonso BA & Tabachnick IA 1967 Biological studies of an antiandrogen (SH-714). European Journal of Pharmacology 1 438-444.
72. O'Dowd GJ, Veltri RW, Orozco R, Miller MC & Oesterling JE 1997 Update on the appropriate staging evaluation for newly-diagnosed prostate-cancer. Journal of Urology 158 687-698.
73. Paulson DF 1980 The prognostic role of lymphadenectomy in adenocarcinoma of the prostate. Urologic Clinics of North America 7 615-622.
74. Pilepich MV, Krall JM, Al-Saffaf M, John MJ, Dogget RL, Sause WT, Lawton CA, Abrams RA, Rotman M, Rubin P et al. 1995 Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45 616-623.
75. Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, Hanks GE, Coughlin CT, Porter A, Shipley WU & Grignon D 1997 Phase III trial of androgen suppression using goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group protocol 85-31. Journal of Clinical Oncology 15 1013-1021.
76. Prostate Cancer Trialists' Collaborative Group 1995 Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomized trials with 3283 deaths in 5710 patients. Lancet 265-269.
77. Rhéaume E, Simard J, Morel Y, Mebarki F, Zachmann M, Forest M, New MI & Labrie F 1992 Congenital adrenal hyperplasia due to point mutations in the type II 3β-hydroxysteroid dehydrogenase gene. Nature Genetics 1 239-245.
78. Simard J, Luthy I, Guay J, Bélanger A & Labrie F 1986 Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues. Molecular and Cellular Endocrinology 44 261-270.
79. Swedish Breast Cancer Cooperative Group 1996 Randomized trial of two versus five years of adjuvant Tamoxifen for postmenopausal early stage breast cancer. Journal of the National Cancer Institute 88 1543-1549.
80. Trapasso JG, deKernion JB, Smith RB & Dorey F 1994 The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. Journal of Urology 152 1821-1825.
81. Waxman JH, Wass JA, Hendry WF, Whitfield HN, Besser GM, Malpas JS & Oliver RT 1983 Treatment with gonadotropin-releasing hormone analogue in advanced prostatic cancer. British Medical Journal Clinical Research Edition 286 1309-1312.
82. Whitmore Jr WF, Warner JA & Thompson IM 1991 Expectant management of localized prostatic cancer. Cancer 67 1091-1096.
83. Zagars GK & von Eschenbach AC 1993 Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiotherapy. Cancer 72 538-548.
84. Zietman AL, Edelstein RA, Coen JJ, Babayan RK & Krane RJ 1994a Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology 43 828-833.
85. 2 adenocarcinoma of the prostate. New insights into outcome from repeat biopsy and prostate specific antigen follow-up. Journal of Urology 152 1806-1812.